Headlines

Novo Nordisk (NVO) US Chief says twice as many medicare patients prefer GLP-1 pill to shot; seeking bolt-on M&A to boost portfolio

Newsquawk Staff ·

Novo Nordisk (NVO) US Chief says twice as many medicare patients prefer GLP-1 pill to shot; seeking bolt-on M&A to boost portfolio.

Related headlines